---
figid: PMC3542227__cbt-13-1376-g5
figtitle: Isolated central nervous system progression on Crizotinib
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3542227
filename: cbt-13-1376-g5.jpg
figlink: /pmc/articles/PMC3542227/figure/F5/
number: F5
caption: Figure 5. Working model for the role of EML4-ALK chimeric kinase in driving
  the progression of NSCLC through activation of the EGFR pathway. The EML4-ALK protein
  phosphorylates and activates Ras signaling leading to a cascade of events driving
  cellular proliferation and growth. There are multiple redundancies in this pathway
  susceptible to targeted small molecule therapy. We propose that using agents such
  as Sorafenib with good CNS penetration distal to ALK-signaling represents an opportunity
  to overcome therapeutic resistance and reduce CNS failure. EGFR, epidermal growth
  factor receptor dimer; AKT, a serine/threonine-specific protein kinase; ERK, extracellular-signal
  related kinases; IKK, IκB kinase; NFκB, nuclear transcription factor kappa B; MEK,
  mitogen-activated protein kinase; RAF, protein serine/threonine protein kinase.
  →, activates; —|, inhibits.
papertitle: Isolated central nervous system progression on Crizotinib.
reftext: Stephen G. Chun, et al. Cancer Biol Ther. 2012 Dec 1;13(14):1376-1383.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.970951
figid_alias: PMC3542227__F5
figtype: Figure
redirect_from: /figures/PMC3542227__F5
ndex: 410bffff-deba-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3542227__cbt-13-1376-g5.html
  '@type': Dataset
  description: Figure 5. Working model for the role of EML4-ALK chimeric kinase in
    driving the progression of NSCLC through activation of the EGFR pathway. The EML4-ALK
    protein phosphorylates and activates Ras signaling leading to a cascade of events
    driving cellular proliferation and growth. There are multiple redundancies in
    this pathway susceptible to targeted small molecule therapy. We propose that using
    agents such as Sorafenib with good CNS penetration distal to ALK-signaling represents
    an opportunity to overcome therapeutic resistance and reduce CNS failure. EGFR,
    epidermal growth factor receptor dimer; AKT, a serine/threonine-specific protein
    kinase; ERK, extracellular-signal related kinases; IKK, IκB kinase; NFκB, nuclear
    transcription factor kappa B; MEK, mitogen-activated protein kinase; RAF, protein
    serine/threonine protein kinase. →, activates; —|, inhibits.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - ALK
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - NFKB1
  - EPHB2
  - MAPK1
  - MAPK3
  - Egfr
  - Alk
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Ras85D
  - Akt
  - Raf
  - Dsor1
  - Mtk
  - IKKepsilon
  - key
  - IKKbeta
  - Dif
  - dl
  - Rel
  - Erk7
  - rl
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
